533 related articles for article (PubMed ID: 29217032)
1. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
Forooghian F; Albiani DA; Kirker AW; Merkur AB
Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
[TBL] [Abstract][Full Text] [Related]
2. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
3. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
Gregori NZ; Flynn HW; Schwartz SG; Rosenfeld PJ; Vaziri K; Moshfeghi AA; Fortun JA; Kovach JL; Dubovy SR; Albini TA; Davis JL; Berrocal AM; Smiddy WE
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):643-8. PubMed ID: 26114845
[TBL] [Abstract][Full Text] [Related]
4. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
[TBL] [Abstract][Full Text] [Related]
6. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
Bavinger JC; Yu Y; VanderBeek BL
Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
[TBL] [Abstract][Full Text] [Related]
7. Effect of a Strict 'No-Talking' Policy During Intravitreal Injection on Post-Injection Endophthalmitis.
Garg SJ; Dollin M; Hsu J; Storey P; Vander JF
Ophthalmic Surg Lasers Imaging Retina; 2015; 46(10):1028-34. PubMed ID: 26599245
[TBL] [Abstract][Full Text] [Related]
8. Association of compounded bevacizumab with postinjection endophthalmitis.
VanderBeek BL; Bonaffini SG; Ma L
JAMA Ophthalmol; 2015 Oct; 133(10):1159-64. PubMed ID: 26270251
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
[TBL] [Abstract][Full Text] [Related]
10. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection.
Storey P; Dollin M; Pitcher J; Reddy S; Vojtko J; Vander J; Hsu J; Garg SJ;
Ophthalmology; 2014 Jan; 121(1):283-289. PubMed ID: 24144453
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.
Papakostas TD; Lim L; van Zyl T; Miller JB; Modjtahedi BS; Andreoli CM; Wu D; Young LH; Kim IK; Vavvas DG; Esmaili DD; Husain D; Eliott D; Kim LA
Eye (Lond); 2016 Jan; 30(1):79-84. PubMed ID: 26449196
[TBL] [Abstract][Full Text] [Related]
12. Acute endophthalmitis after intravitreal injection and preventive effect of preoperative topical antibiotics.
Park Y; Kim KS; Park YH
J Ocul Pharmacol Ther; 2013 Dec; 29(10):900-5. PubMed ID: 24067061
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
[TBL] [Abstract][Full Text] [Related]
14. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S
Retina; 2008; 28(10):1395-9. PubMed ID: 18827737
[TBL] [Abstract][Full Text] [Related]
15. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
[TBL] [Abstract][Full Text] [Related]
16. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL;
Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
18. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait.
Wani VB; Al-Kandari J; Sabti K; Aljassar F; Qali H; Kumar N; Uboweja A; Al-Sabah K; Diab FA; Al-Rashidi S
Middle East Afr J Ophthalmol; 2016; 23(1):64-70. PubMed ID: 26957841
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]